Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
Bijay S. Jaiswal, Vasantharajan Janakiraman, Noelyn M. Kljavin et al. · 2009
Read Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors by Bijay S. Jaiswal, Vasantharajan Janakiraman, Noelyn M. Kljavin et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0005717.txt.
Description
Bijay Jaiswal and colleagues reported in 2009 that tumors with a mutated NRAS gene need a two-pronged drug attack. RAS genes are proven cancer drivers, yet no drug has blocked RAS itself well in patients. So researchers target the helper paths that carry RAS signals instead.
The team found that blocking BRAF alone is not enough in NRAS-mutant tumors. Adding a block on CRAF, or on the PI3K path, made treatment work. That pairing rule can guide drug trials for a stubborn tumor class. It also shows why single drugs so often fail against RAS cancers.
Catalog record
| CREATOR | Bijay S. Jaiswal, Vasantharajan Janakiraman, Noelyn M. Kljavin et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005717